[{"id":"883429dd-80b1-4a90-8bbc-e9d0771addf2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07135804","created_at":"2025-08-30T14:01:57.585Z","updated_at":"2025-08-30T14:01:57.585Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT07135804","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2025-08-22"},{"id":"c1e23e3e-f08f-4c83-8bab-2ac3f776fe0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07088861","created_at":"2025-08-02T14:24:41.757Z","updated_at":"2025-08-02T14:24:41.757Z","phase":"","brief_title":"Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China","source_id_and_acronym":"NCT07088861","lead_sponsor":"Lirong Wu","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1401","initiation":"Initiation: 01/26/2011","start_date":" 01/26/2011","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-07-28"},{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"e6b99f28-6a26-4cf9-aa0c-52200cf1061c","acronym":"ECOG-ACRIN EA3202","url":"https://clinicaltrials.gov/study/NCT05063552","created_at":"2021-10-01T12:54:14.078Z","updated_at":"2025-02-25T12:28:23.682Z","phase":"Phase 2/3","brief_title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","source_id_and_acronym":"NCT05063552 - ECOG-ACRIN EA3202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/15/2027","primary_completion_date":" 12/15/2027","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2025-02-24"},{"id":"72d8c724-8d53-4e69-afd5-a79ba1831075","acronym":"REMAIN","url":"https://clinicaltrials.gov/study/NCT06029270","created_at":"2023-09-08T20:10:10.653Z","updated_at":"2025-02-25T13:55:33.082Z","phase":"Phase 2","brief_title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","source_id_and_acronym":"NCT06029270 - REMAIN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/15/2024","start_date":" 07/15/2024","primary_txt":" Primary completion: 04/30/2029","primary_completion_date":" 04/30/2029","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"},{"id":"6012d2b0-c674-470f-8b4e-8b5f593328fd","acronym":"NEOSPACE","url":"https://clinicaltrials.gov/study/NCT03734809","created_at":"2021-01-18T18:17:38.881Z","updated_at":"2025-02-25T14:40:02.842Z","phase":"Phase 2","brief_title":"NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer","source_id_and_acronym":"NCT03734809 - NEOSPACE","lead_sponsor":"Chinese University of Hong Kong","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • gemcitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 05/03/2019","start_date":" 05/03/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-14"},{"id":"d4207de7-4d28-4ffe-a877-c2adf5f87729","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904080","created_at":"2023-06-15T18:09:01.233Z","updated_at":"2025-02-25T15:28:06.715Z","phase":"Phase 2","brief_title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","source_id_and_acronym":"NCT05904080","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/19/2024","start_date":" 02/19/2024","primary_txt":" Primary completion: 06/16/2028","primary_completion_date":" 06/16/2028","study_txt":" Completion: 06/16/2028","study_completion_date":" 06/16/2028","last_update_posted":"2025-02-12"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"bd048b8e-a7db-4137-9356-c4eef9e3d0d4","acronym":"BGB-A317-A445-101","url":"https://clinicaltrials.gov/study/NCT04215978","created_at":"2022-08-30T23:00:45.831Z","updated_at":"2025-02-25T16:37:41.515Z","phase":"Phase 2","brief_title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04215978 - BGB-A317-A445-101","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-A445"],"overall_status":"Completed","enrollment":" Enrollment 204","initiation":"Initiation: 01/30/2020","start_date":" 01/30/2020","primary_txt":" Primary completion: 01/24/2025","primary_completion_date":" 01/24/2025","study_txt":" Completion: 01/24/2025","study_completion_date":" 01/24/2025","last_update_posted":"2025-02-06"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"af8b0fde-0cd4-4b0c-bf7d-ca9f737f567b","acronym":"AK104-IIT-019","url":"https://clinicaltrials.gov/study/NCT05587374","created_at":"2025-02-25T19:03:11.402Z","updated_at":"2025-02-25T19:03:11.402Z","phase":"Phase 3","brief_title":"Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)","source_id_and_acronym":"NCT05587374 - AK104-IIT-019","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Kaitanni (cadonilimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-01-23"},{"id":"d1ef715c-a9d2-435d-8f89-9b22030ab5c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06749899","created_at":"2025-02-26T08:08:39.879Z","updated_at":"2025-02-26T08:08:39.879Z","phase":"Phase 3","brief_title":"QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.","source_id_and_acronym":"NCT06749899","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 12/19/2024","start_date":" 12/19/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-12-27"},{"id":"6bf2b896-e018-4a72-8241-0b41b1b66f40","acronym":"","url":"https://clinicaltrials.gov/study/NCT06118333","created_at":"2023-11-07T20:13:25.871Z","updated_at":"2025-02-25T15:36:37.862Z","phase":"Phase 3","brief_title":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT06118333","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • capecitabine • izalontamab brengitecan (BL-B01D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 368","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-18"},{"id":"4a6eacc1-75d0-46af-9a1d-a8fa1cb491d9","acronym":"PLATINUM","url":"https://clinicaltrials.gov/study/NCT03984357","created_at":"2024-02-06T19:19:46.889Z","updated_at":"2025-02-25T14:28:25.264Z","phase":"Phase 2","brief_title":"Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT03984357 - PLATINUM","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2024-05-29"},{"id":"b2d0e16f-9f16-4b18-afd1-1b771c949f14","acronym":"","url":"https://clinicaltrials.gov/study/NCT05955105","created_at":"2024-05-21T20:33:37.710Z","updated_at":"2024-07-02T16:35:02.295Z","phase":"Phase 1/2","brief_title":"A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT05955105","lead_sponsor":"Innolake Biopharm","biomarkers":" PD-L1 • TMB • MSI • CD8 • CD68","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • MSI • CD8 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • ILB-2109"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/25/2023","start_date":" 07/25/2023","primary_txt":" Primary completion: 01/25/2026","primary_completion_date":" 01/25/2026","study_txt":" Completion: 07/24/2026","study_completion_date":" 07/24/2026","last_update_posted":"2024-05-21"},{"id":"b5c251af-5a64-49c1-9a43-551cf4714f26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05581550","created_at":"2022-10-14T15:10:29.389Z","updated_at":"2024-07-02T16:35:02.175Z","phase":"","brief_title":"Somatostatin Receptor Imaging in NPC, EBV Related Cancers","source_id_and_acronym":"NCT05581550","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-21"},{"id":"cd2f0c6b-9287-4ecc-b80c-c18fadf4071e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03074513","created_at":"2021-01-19T13:46:53.660Z","updated_at":"2024-07-02T16:35:03.337Z","phase":"Phase 2","brief_title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","source_id_and_acronym":"NCT03074513","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-16"},{"id":"0231e8aa-90a2-4a9d-a7ab-41dc306390b9","acronym":"NPC-Nivo","url":"https://clinicaltrials.gov/study/NCT06019130","created_at":"2023-08-31T13:09:35.180Z","updated_at":"2024-07-02T16:35:03.620Z","phase":"Phase 2","brief_title":"Nivolumab in Children and Adults With Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT06019130 - NPC-Nivo","lead_sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • 5-fluorouracil"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 01/10/2023","start_date":" 01/10/2023","primary_txt":" Primary completion: 01/09/2026","primary_completion_date":" 01/09/2026","study_txt":" Completion: 01/09/2028","study_completion_date":" 01/09/2028","last_update_posted":"2024-05-15"},{"id":"e994ddd8-c8c2-48db-9917-ca57ceffe9a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04995185","created_at":"2021-08-06T12:53:11.830Z","updated_at":"2024-07-02T16:35:03.536Z","phase":"","brief_title":"18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study","source_id_and_acronym":"NCT04995185","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" HIF1A • CA9","pipe":" | ","alterations":" HIF1A expression • VEGFA expression • CA9 expression","tags":["HIF1A • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression • VEGFA expression • CA9 expression"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/20/2017","start_date":" 06/20/2017","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2024-05-15"},{"id":"e010692c-cb34-4f60-9f7a-ecc27d66d264","acronym":"","url":"https://clinicaltrials.gov/study/NCT06383507","created_at":"2024-04-25T20:52:17.445Z","updated_at":"2024-07-02T16:35:07.514Z","phase":"Phase 1","brief_title":"A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT06383507","lead_sponsor":"Zhejiang University","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/22/2024","start_date":" 04/22/2024","primary_txt":" Primary completion: 04/21/2027","primary_completion_date":" 04/21/2027","study_txt":" Completion: 04/21/2029","study_completion_date":" 04/21/2029","last_update_posted":"2024-04-25"},{"id":"b7a36882-65b3-44a2-abdd-b0fe4500256d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03809624","created_at":"2021-07-22T21:52:31.520Z","updated_at":"2024-07-02T16:35:18.390Z","phase":"Phase 2","brief_title":"Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer","source_id_and_acronym":"NCT03809624","lead_sponsor":"Inhibrx, Inc.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enristomig (INBRX-105)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-21"},{"id":"82abbfb4-9687-48c6-8688-0f55469253e1","acronym":"DUET-3","url":"https://clinicaltrials.gov/study/NCT03752398","created_at":"2021-01-18T18:26:08.585Z","updated_at":"2024-07-02T16:35:19.743Z","phase":"Phase 1","brief_title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","source_id_and_acronym":"NCT03752398 - DUET-3","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • izuralimab (XmAb23104)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-12"},{"id":"c271790d-65c3-4f5e-b3cd-f73d35fd1790","acronym":"DIAMOND","url":"https://clinicaltrials.gov/study/NCT04907370","created_at":"2024-02-06T20:20:17.343Z","updated_at":"2024-07-02T16:35:20.648Z","phase":"Phase 3","brief_title":"PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT04907370 - DIAMOND","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-02-06"},{"id":"24101395-efd5-45f7-b263-ca1e7f90853b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02915445","created_at":"2021-01-18T14:18:46.620Z","updated_at":"2024-07-02T16:35:28.369Z","phase":"Phase 1","brief_title":"EpCAM CAR-T for Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT02915445","lead_sponsor":"Sichuan University","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-22"}]